Skip to main content
Breast

Breast Disease

Cysts, cancer, diagnosis, genetics, and multidisciplinary care

Imaging + biopsy + tumor biology (ER/PR/HER2) define the real pathway — not fear alone.

Not every breast lump is cancer — but I do not guess when something is new or changing. Triple assessment (exam, imaging, pathology) prevents both missed cancers and unnecessary mastectomy from fear alone. Tumor biology (ER/PR/HER2/Ki-67) shapes chemotherapy, endocrine therapy, and anti-HER2 options. I offer BRCA1/2 testing to newly diagnosed patients ≤65; above 65 the decision is individualized. Neoadjuvant therapy can reshape breast and axillary plans — the first sketch is not always the final map.

Breast Disease
  • Hero figure: breast anatomy and disease overview for education.
  • Related figures support benign disease, cancer work-up, and surgical pathway concepts.

Educational figures

Tap a figure to enlarge. These English illustrations mirror the Turkish hub gallery for this condition.

  • Diagnosis
  • Cancer
  • Treatment
  • Multidisciplinary

What to know

  • Genetic testing frame

    Key note inside

    Newly diagnosed patients ≤65 are generally offered BRCA1/2 testing; above 65, testing is individualized (e.g., triple-negative, male breast cancer, bilateral disease, strong family history).

  • Not every lump is cancer

    Cysts and fibroadenomas are common — characterization prevents overtreatment while still catching malignancy.

  • Surgery is not a slogan

    Breast-conserving surgery and mastectomy are chosen by tumor size, biology, genetics, reconstruction wishes, and oncologic margins — not by “safer equals more tissue removed.”

  • Neoadjuvant can redraw the map

    After systemic therapy, breast and axillary plans are reassessed. The initial recommendation is a starting point, not a locked vow.

  • Multidisciplinary care

    Surgery, medical oncology, radiation, genetics, and reconstruction share decisions so sequencing serves the whole pathway.

What happens next

Simple cysts, fibroadenoma, and when biopsy is discussed

Oncologic surgery6 chapters

Scientific evidence atlas

Plain-language summaries of the key clinical trials behind current treatment decisions.

Evidence

Scientific sources

Show sources · 4

Selected guidelines for breast cancer surgery, systemic options, germline testing, and selected early-stage SLNB omission. Ki-67 alone does not decide chemotherapy.

  1. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upESMO · 2024 · DOI: 10.1016/j.annonc.2023.11.016Open source
  2. NCCN Guidelines — Breast CancerNCCN · Current versionOpen source
  3. ASCO–SSO germline testing in patients with breast cancer (guideline framework)American Society of Clinical Oncology / Society of Surgical Oncology · 2024 frameworkOpen source
  4. Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline UpdateAmerican Society of Clinical Oncology (ASCO) · 2025 · DOI: 10.1200/JCO-25-00099Open source

Source list last checked: 21 August 2026. (Page content review date may appear separately above.)

Appointment / info

Bring mammogram/ultrasound/MRI CDs and pathology — biology and imaging decide more than fear alone.

This page is for education. It is not medical advice and does not replace a visit with your physician.

Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · English patient-education hub.